OBJECTIVE:: Evaluate the impact of a comprehensive diabetes disease management (DM) program on healthcare costs, quality of life and patient satisfaction. METHODS: Diabetes patients targeted by pharmacy claims were invited to enroll in a voluntary payor-sponsored DM program (n=2,745). Eligible non-enrollees were used for the control group (n=8,978). Medical and pharmacy claims were combined to determine healthcare costs. Quality of life and patient satisfaction were also assessed, via patient interview. The analysis timeframe encompassed two years prior and one year following program initiation. RESULTS: Enrollees had higher direct healthcare costs than non-enrollees. We were able to predict accurately the medical spend in our control group in absence of intervention with standard time series analysis within 4%. Following DM intervention, enrollees’ healthcare spend was lower than their baseline spend and lower than their projected spend (-$116, -$1,056). Conversely, healthcare spend increased in the non-enrollee group from baseline (+$714) (Table 1). Additionally, enrollee quality of life measures improved from baseline and patient satisfaction with the DM program was high. CONCLUSIONS: A comprehensive diabetes DM program can lower healthcare cost and improve patient reported quality of life while demonstrating consistently high patient satisfaction.